NAD+: What the Current Evidence Does and Does Not Show
A 2026 systematic review summarises preclinical and clinical research on NAD+ supplementation for ageing and wellness.
NAD+ is a molecule the body uses in energy metabolism, and its levels decline with age. A 2026 systematic review in Ageing Research Reviews found that much of the evidence is preclinical, and that human studies are generally small and short.
Small human studies have looked at NAD+ given by intravenous infusion, including a 2019 pilot study (PMID 31572171) and a 2026 tolerability pilot (PMID 41704678). These studies describe how the body handles NAD+ and how well it is tolerated; they do not show that it slows ageing.
Key takeaways
- Human evidence is early and limited.
- Most human studies used IV infusion, not self-administration.
- No proven anti-ageing effect in humans.
Educational only. Not medical advice. SEIVA protocols are prescribed only after physician review and telehealth consultation.